Market Closed -
NSE India S.E.
03:15:43 2024-05-18 am EDT
|
5-day change
|
1st Jan Change
|
808
INR
|
+4.09%
|
|
+5.56%
|
+19.57%
|
Fiscal Period: March |
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
44,676
|
39,940
|
79,573
|
-
|
-
|
Enterprise Value (EV)
1 |
44,676
|
38,922
|
65,153
|
77,599
|
76,499
|
P/E ratio
|
41
x
|
47.4
x
|
54.9
x
|
52.3
x
|
42.4
x
|
Yield
|
0.23%
|
0.26%
|
0.18%
|
0.19%
|
0.24%
|
Capitalization / Revenue
|
9.66
x
|
8.7
x
|
11.9
x
|
11.7
x
|
10
x
|
EV / Revenue
|
9.66
x
|
8.48
x
|
11.9
x
|
11.4
x
|
9.62
x
|
EV / EBITDA
|
21.9
x
|
21.4
x
|
29.5
x
|
28.1
x
|
23.4
x
|
EV / FCF
|
125
x
|
97.9
x
|
-147
x
|
62.8
x
|
36.2
x
|
FCF Yield
|
0.8%
|
1.02%
|
-0.68%
|
1.59%
|
2.76%
|
Price to Book
|
9.54
x
|
7.33
x
|
12.4
x
|
10.1
x
|
8.38
x
|
Nbr of stocks (in thousands)
|
101,966
|
102,071
|
102,516
|
-
|
-
|
Reference price
2 |
438.2
|
391.3
|
776.2
|
776.2
|
776.2
|
Announcement Date
|
5/26/22
|
5/29/23
|
5/8/24
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
4,624
|
4,592
|
5,478
|
6,787
|
7,954
|
EBITDA
1 |
-
|
2,037
|
1,820
|
2,209
|
2,763
|
3,265
|
EBIT
1 |
-
|
1,510
|
1,203
|
1,639
|
2,088
|
2,523
|
Operating Margin
|
-
|
32.66%
|
26.2%
|
29.92%
|
30.76%
|
31.72%
|
Earnings before Tax (EBT)
1 |
-
|
1,474
|
1,135
|
1,587
|
2,025
|
2,514
|
Net income
1 |
842.6
|
1,097
|
846.3
|
1,188
|
1,518
|
1,884
|
Net margin
|
-
|
23.72%
|
18.43%
|
21.69%
|
22.36%
|
23.69%
|
EPS
2 |
8.260
|
10.69
|
8.260
|
11.59
|
14.84
|
18.30
|
Free Cash Flow
1 |
-
|
356.5
|
397.7
|
-528
|
1,235
|
2,112
|
FCF margin
|
-
|
7.71%
|
8.66%
|
-9.76%
|
18.19%
|
26.55%
|
FCF Conversion (EBITDA)
|
-
|
17.5%
|
21.85%
|
-
|
44.69%
|
64.68%
|
FCF Conversion (Net income)
|
-
|
32.5%
|
46.99%
|
-
|
81.37%
|
112.09%
|
Dividend per Share
2 |
-
|
1.000
|
1.000
|
1.420
|
1.500
|
1.900
|
Announcement Date
|
6/5/21
|
5/26/22
|
5/29/23
|
5/8/24
|
-
|
-
|
Fiscal Period: March |
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
1,108
|
1,162
|
1,044
|
1,207
|
1,131
|
1,210
|
1,210
|
1,369
|
1,321
|
1,493
|
EBITDA
1 |
-
|
478.3
|
478.6
|
398.9
|
487.4
|
442.9
|
491.1
|
481.2
|
553.5
|
520.2
|
608
|
EBIT
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
-
|
237.2
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net income
1 |
277.1
|
252.9
|
-
|
174.5
|
233.3
|
163.6
|
274.9
|
263.8
|
311
|
277
|
308
|
Net margin
|
-
|
22.83%
|
-
|
16.72%
|
19.32%
|
14.47%
|
22.72%
|
21.8%
|
22.72%
|
20.97%
|
20.63%
|
EPS
|
2.700
|
2.460
|
-
|
1.700
|
2.270
|
1.600
|
-
|
-
|
-
|
-
|
3.000
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/8/21
|
2/4/22
|
5/26/22
|
8/9/22
|
11/10/22
|
2/13/23
|
5/29/23
|
8/9/23
|
-
|
-
|
-
|
Fiscal Period: March |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
1,019
|
1,708
|
1,974
|
3,074
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
357
|
398
|
-528
|
1,235
|
2,112
|
ROE (net income / shareholders' equity)
|
-
|
26.5%
|
16.7%
|
19.5%
|
20.8%
|
21.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-
|
45.90
|
53.40
|
62.60
|
76.90
|
92.60
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
1,223
|
1,248
|
2,331
|
1,177
|
1,129
|
Capex / Sales
|
-
|
26.46%
|
27.19%
|
43.1%
|
17.34%
|
14.2%
|
Announcement Date
|
6/5/21
|
5/26/22
|
5/29/23
|
5/8/24
|
-
|
-
|
Last Close Price
776.2
INR Average target price
750.6
INR Spread / Average Target -3.29% Consensus |
1st Jan change
|
Capi.
|
---|
| +19.57% | 955M | | -16.99% | 8.55B | | +65.23% | 4.24B | | -1.63% | 2.54B | | -10.68% | 2.44B | | -41.76% | 2.35B | | -8.53% | 1.89B | | -19.29% | 1.55B | | -39.61% | 1.23B | | +9.54% | 1.13B |
Medical & Diagnostic Laboratories
|